GT
AVBP icon

Glenmede Trust’s ArriVent BioPharma AVBP Stock Holding History

Glenmede Trust’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346K Buy
9,970
+909
+10% +$26.8K ﹤0.01% 1123
2026
Q1 		$209K Buy
+9,061
New +$205K ﹤0.01% 1290

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Glenmede Trust's AVBP Position: Q2 2026 in Review

Glenmede Trust increased its ArriVent BioPharma (AVBP) stake by 10% in Q2 2026, buying an estimated $26.8K and bringing the position to 9,970 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #1123.

Glenmede Trust first reported a position in AVBP in Q1 2026 and has held it in 2 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Glenmede Trust held 9,970 shares of ArriVent BioPharma worth $346K as of Q2 2026.
  • Glenmede Trust bought 909 ArriVent BioPharma shares in Q2 2026, an estimated $26.8K.
  • ArriVent BioPharma made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1123 holding.
  • Glenmede Trust first reported a position in ArriVent BioPharma in Q1 2026 and has held it in 2 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.